A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
复制标题
多西紫杉醇和卡铂治疗非小细胞肺癌的 II 期研究。
DOI：
10.1016/s0169-5002(00)00226-9
复制
发表时间：
2001
期刊：
影响因子：
5.3
通讯作者：
D. Patakas
中科院分区：
文献类型：
--
作者：
K. Zarogoulidis;T. Kontakiotis;P. Hatziapostolou;E. Fachantidou;D. Delis;J. Goutsikas;T. Constantinidis;A. Athanasiadis;D. Patakas
我们研究了多西紫杉醇(D)联合卡铂(C)治疗非小细胞肺癌（NSCLC）患者的疗效。自1996年以来，123例无法手术的非小细胞肺癌患者被纳入研究；共120例（男108例，女12例，平均年龄58.0±8.3岁）。其中46例为鳞状癌，44例为腺癌，11例为大细胞癌，19例为未分化肿瘤。入选标准包括：证实不能手术的非小细胞肺癌、WHO表现状态（PS） 0-1、年龄70岁及肝肾功能正常。总共进行了622个化疗周期（CHT）（中位数为7个（95% CI 6.2-7.47），每个患者疗程）。每个周期由100 mg/m2的多西紫杉醇以第1天曲线下面积（AUC）为6的剂量输注C 2小时组成。该方案每28天重复8个周期。在患者中，5例（4%）达到完全缓解，49例（40%）达到部分缓解，47例（39%）病情稳定，19例（15%）病情进展。所有患者的中位生存期为12个月，4例IIb期患者为12个月，IIIa期患者为18个月，29例IIIb期患者为20个月，65例IV期患者为11个月。中位进展时间为8个月（90例）。毒性：3/4级中性粒细胞减少，18例（15%）；3/4级贫血6例（5%）；可耐受周围神经病变16例（13.3%）。应答者在第6 ~ 8周期间接受放疗（总剂量，4周50 Gy）。在IIIb期首发患者中，有7例（5%）接受了手术切除。疾病早期进展的患者在第2和第3周期接受相同剂量的放疗。该研究仍在进行中，6名患者（5%）在3年后仍然存活。初步结果表明，D/C联合治疗非小细胞肺癌非常有效，且毒性耐受。对于不能手术的非小细胞肺癌患者，这种药物组合也可以作为新辅助治疗。
We investigated the efficacy of docetaxel (D) in combination with carboplatin (C) in the treatment of non-small cell lung cancer (NSCLC) patients. Since 1996, 123 with inoperable NSCLC were enrolled in the study; 120 (108 males, 12 females; mean age 58.0±8.3 years) were evaluated. Of those, 46 patients had squamous carcinoma, 44 adenocarcinoma, 11 large cell carcinoma and 19 undifferentiated tumours. Eligibility criteria included, documented inoperable NSCLC, WHO performance status (PS) 0–1, age up to 70 years, and normal renal and hepatic function. A total of 622 cycles of chemotherapy (CHT) (median 7 (95% CI 6.2–7.47), courses per patient) were administered. Each cycle consisted of 100 mg/m2of docetaxel in a 2-h infusion with C at a dose of area under the curve (AUC) of 6 on day 1. This regimen was repeated every 28 days up to eight cycles. Of the patients, five (4%) achieved complete response, 49 (40%) partial response, 47 (39%) had stable disease and 19 (15%) had progressive disease. The median survival was 12 months for all patients, 12 for the four patients with stage IIb disease, 18 for the patients with stage IIIa disease, 20 for the 29 patients with stage IIIb disease, and 11 for the 65 stage IV patients. The median time to progression was 8 months (90 patients). Toxicity was, grade 3/4 neutropenia, 18 patients (15%); grade 3/4 anaemia, 6 patients (5%); and tolerable peripheral neuropathy, 16 patients (13.3%). Responders received radiotherapy (total dose, 50 Gy in 4 weeks) between the 6th and 8th cycle. Among responders with initial stage IIIb disease, 7 (5%) underwent surgical resection. Patients with early progression of the disease received the same dose of radiotherapy between 2nd and 3rd cycle. The study is ongoing, and six patients (5%) are still alive (after 3 years). Preliminary results indicate that the D/C combination is very active in the treatment of NSCLC with tolerable toxicity. It appears that this drug combination is also good as neoadjuvant therapy in inoperable NSCLC patients.
影响因子：
45.3
作者：
FINKELSTEIN, DM;ETTINGER, DS;RUCKDESCHEL, JC
通讯作者：
RUCKDESCHEL, JC
DOI：
--
发表时间：
1998-05
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
P. Bunn;K. Kelly
通讯作者：
P. Bunn;K. Kelly
影响因子：
158.5
作者：
DILLMAN, RO;SEAGREN, SL;GREEN, MR
通讯作者：
GREEN, MR